Repligen(RGEN) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $198 million, representing an 18% year-over-year increase and 14% organic growth, exceeding guidance [6][24] - Full year revenue reached $738 million, with a reported growth of 16% and 14% organic growth, surpassing initial guidance [7][24] - Adjusted operating margin for the fourth quarter was 15%, reflecting a 10 basis point increase year-over-year, and 240 basis points expansion excluding M&A and foreign currency impacts [27][28] Business Line Data and Key Metrics Changes - Protein and process analytics segments both grew over 30% in the fourth quarter, while chromatography grew more than 25% [7][19] - Filtration revenue grew high single digits for both the quarter and the year, driven by consumables [8][18] - New modalities grew low single digits for the year, with strength in cell therapy but headwinds in mRNA demand [11][12] Market Data and Key Metrics Changes - North America accounted for approximately 47% of total revenue, growing mid-teens, while EMEA grew over 20% [25] - Asia Pacific grew high teens, with China showing signs of recovery after a decline in 2025 [25] - Biopharma revenue grew over 20% year-over-year, with strong growth across all geographies [11] Company Strategy and Development Direction - The company aims to outpace bioprocessing industry growth, drive operating leverage, and continue innovation through new product launches [22][23] - Focus on integrating recent acquisitions and pursuing additional M&A opportunities remains a priority [16][23] - The company is committed to margin expansion while balancing investments for future growth [10][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about a strengthening macro backdrop, including improved biotech funding and positive pharma sentiment [10] - The guidance for 2026 anticipates revenue between $810 million and $840 million, reflecting 9%-13% organic growth [9][32] - Management acknowledged potential headwinds from FDA policy and biopharma's strategic responses to market changes [10][11] Other Important Information - The company expanded adjusted operating margin by 90 basis points to 13.8% in 2025, with significant investments in leadership and technology [14][28] - Cash and marketable securities at the end of the fourth quarter totaled $768 million, up $90 million sequentially [30][31] Q&A Session Summary Question: Can you provide insights on the guidance and customer confidence regarding the policy environment? - Management noted that tariffs are a significant open question but do not create substantial noise in sales, with a strong funnel of opportunities being tracked [40][42][44] Question: How does margin expansion rank relative to M&A priorities? - Management emphasized that margin expansion remains a top priority, alongside above-market growth, while acknowledging the strategic merits of potential acquisitions [47][49] Question: What are the expectations for pacing and market normalization in 2026? - Management indicated that while there are strong opportunities, macro factors could influence CapEx spending decisions, leading to a cautious approach in guidance [56][58] Question: Can you clarify the organic growth expectations for Q1 and the overall guidance? - Management expects Q1 to be only slightly down sequentially from Q4 2025, indicating a strong start to the year [63][64] Question: What is the outlook for the analytics portfolio given the growth forecast? - Management expressed confidence in achieving over 20% growth in analytics, driven by the ongoing upgrade cycle of the SoloVPE PLUS System and the expanded product portfolio from recent acquisitions [82][84]